Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
NHS access to GLP-1 medicines
The honest picture of how GLP-1 medicines (Wegovy, Mounjaro, Saxenda) are accessed on the NHS in 2026 — eligibility, the service pathway, and realistic expectations on wait times. Educational only; confirm current NICE guidance and local commissioning with your GP.
The two NHS access doors
- Type 2 diabetes pathway — Ozempic, Mounjaro, and Victoza are routinely prescribed in NHS diabetes services for type 2 diabetes when they fit treatment criteria. The GP or diabetes specialist makes that call.
- Weight management pathway — Wegovy, Mounjaro and Saxenda may be accessed through specialist weight management services (sometimes called tier 3 services). Eligibility is set by NICE guidance and varies by local commissioning.
The weight-management door is where most public confusion sits. Demand massively outstrips supply, and the system is rationed.
Weight-management eligibility — the rough picture
Specific NICE technology appraisal criteria evolve. The general NICE-eligible profile has historically required:
- A BMI in a defined threshold (often BMI ≥35 with weight-related comorbidities, or BMI ≥30 in some specific groups).
- A weight-related health condition such as type 2 diabetes, prediabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease.
- Access via a specialist weight-management service rather than direct GP prescription.
Your local Integrated Care Board (ICB) commissions weight-management services; what is available in your area can differ materially from what is available a few miles away. Your GP can refer if you meet the criteria.
Confirm current NICE guidance before drawing conclusions. The technology appraisals change; what was true a year ago may not be true today.
Realistic wait times
Specialist weight-management service waits are long in most areas — months to over a year is not unusual. Some areas have waiting lists that are effectively closed. This is one reason people turn to private routes, with all the risks that brings if the private provider is unregulated.
What the NHS will not do
- Prescribe GLP-1 medicines on direct patient request without meeting eligibility criteria.
- Continue GLP-1 prescribing started privately without taking over clinical responsibility — most GPs will not "carry on" a private prescription.
- Cover cosmetic weight loss outside the NICE-approved indications.
If you don't qualify for NHS access
A regulated private prescription is the lawful alternative. Don't let an NHS rejection push you toward unregulated online sellers or social-media supply — the safety risks are real. See:
Questions for your GP
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Do I meet current NICE eligibility criteria for NHS GLP-1 access for my situation?
- What is the local weight-management service pathway and the current waiting time?
- If I start a private prescription, will the NHS take over the prescribing later?
- If I do qualify, which GLP-1 medicine is the right starting point for me?
- Are there licensed alternatives (other weight-management interventions) I should consider first?